生物科技B類股全線上漲 信達生物-B(1801.HK)漲超10%領漲
格隆匯6月1日丨週末全球新增新冠肺炎病例再創單日新高,港股市場生物科技B類股集體走強且整體漲幅靠前。其中,信達生物-B漲超10%領漲,啟明醫療-B漲超9%,康方生物-B、基石藥業-B、康希諾生物-B均漲超6%,沛嘉醫療-B漲超5%,君實生物-B、諾誠健華-B和復宏漢霖-B漲超4%。5月30日全球新增新冠肺炎確診病例13.5萬例,再創單日新高;5月31日全球新增確診病例10.79萬例。另外,信達生物-B領漲板塊,公司和禮來製藥(LLY.US)共同宣佈在第56屆美國臨牀腫瘤學會年會(ASCO)上通過壁報討論的形式公佈了雙方共同開發的信迪利單抗二線治療局部晚期或轉移性食管鱗癌(ORIENT-2)的關鍵臨牀研究結果。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.